ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Hoffmann-La Roche and Johnson & Johnson side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Hoffmann-La RocheJohnson & Johnson
studies on the registry2,7443,709
open to participants now114146
phase 3 studies under way9595
reach primary completion within a year7687
programswith a study of their own in two years80+25 named only56+4 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseHoffmann-La RocheJohnson & Johnson
Phase 1

Hoffmann-La Roche: 33 of its 80 programs at phase 1

  1. RAY121phase 1
  2. clesitamigphase 1
  3. P-CD19CD20-ALLO1 Cellsphase 1
  4. Anti-c-Met Antibody-drug Conjugate YL211phase 1
  5. AQUA07phase 1

and 28 more — sign in to see them all

41%

Johnson & Johnson: 26 of its 56 programs at phase 1

  1. Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543phase 1
  2. Anti-PSMA Antibody-drug Conjugate ARX517phase 1
  3. JNJ-86974680phase 1
  4. JNJ-87801493phase 1
  5. JNJ-64264681phase 1

and 21 more — sign in to see them all

46%
Phase 2

Hoffmann-La Roche: 18 of its 80 programs at phase 2

  1. tifeglipronphase 2
  2. autogene cevumeranphase 2
  3. hyaluronidase (human recombinant)phase 2
  4. RO7568282phase 2
  5. tambotatug pelitecanphase 2

and 13 more — sign in to see them all

23%

Johnson & Johnson: 8 of its 56 programs at phase 2

  1. JNJ-95597528phase 2
  2. anvatabart opadotinphase 2
  3. fludarabinephase 2
  4. JNJ-64042056phase 2
  5. JNJ-88545223phase 2

and 3 more — sign in to see them all

14%
Phase 3

Hoffmann-La Roche: 22 of its 80 programs at phase 3

  1. inavolisibphase 3
  2. afimkibartphase 3
  3. giredestrantphase 3
  4. divarasibphase 3
  5. glofitamabphase 3

and 17 more — sign in to see them all

28%

Johnson & Johnson: 18 of its 56 programs at phase 3

  1. amivantamabphase 3
  2. nipocalimabphase 3
  3. ramantamigphase 3
  4. icotrokinraphase 3
  5. lumateperonephase 3

and 13 more — sign in to see them all

32%
Approved, new studies

Hoffmann-La Roche: 7 of its 80 programs at approved, new studies

  1. ocrelizumabapproved, new study
  2. Ranibizumabapproved, new study
  3. emicizumabapproved, new study
  4. faricimabapproved, new study
  5. Trastuzumabapproved, new study

and 2 more — sign in to see them all

9%

Johnson & Johnson: 4 of its 56 programs at approved, new studies

  1. guselkumabapproved, new study
  2. teclistamabapproved, new study
  3. ibrutinibapproved, new study
  4. Esketamineapproved, new study
7%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Hoffmann-La Roche27 readouts · 7 phase 3

Hoffmann-La Roche, Nov ’26: 1 program whose next study reaches primary completion

  1. divarasibphase 3 · Nov 30 · NCT04302025

Hoffmann-La Roche, Dec ’26: 4 programs whose next study reaches primary completion

  1. RG6496phase 1 · Dec 1 · NCT07246941
  2. tifeglipronphase 2 · Dec 7 · NCT06982131
  3. afimkibartphase 3 · Dec 31 · NCT05910528
  4. inavolisibphase 3 · Dec 31 · NCT03006172

Hoffmann-La Roche, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. faricimabapproved, new study · Jan 26 · NCT05224102

Hoffmann-La Roche, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. Ranibizumabapproved, new study · Feb 4 · NCT04657289
  2. cevostamabphase 3 · Feb 26 · NCT05535244

Hoffmann-La Roche, Mar ’27: 4 programs whose next study reaches primary completion

  1. pegozaferminphase 3 · Mar 2 · NCT07835243
  2. glofitamabphase 3 · Mar 22 · NCT06624085
  3. RAY121phase 1 · Mar 31 · NCT06371417
  4. RO7812653phase 1 · Mar 31 · NCT07234942

Hoffmann-La Roche, Apr ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. enicepatidephase 3 · Apr 8 · NCT07626515
  2. Crovalimabphase 3 · Apr 18 · NCT04432584
  3. baloxavirphase 3 · Apr 30 · NCT07827599

Hoffmann-La Roche, May ’27: 1 program whose next study reaches primary completion

  1. RO7806881phase 1 · May 11 · NCT07271693

Hoffmann-La Roche, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. fenebrutinibphase 3 · Jun 8 · NCT07161258
  2. DONQ52phase 2 · Jun 15 · NCT07239336
  3. RO7890597phase 1 · Jun 15 · NCT07797478
  4. astegolimabphase 3 · Jun 30 · NCT05878769

Hoffmann-La Roche, Jul ’27: 2 programs whose next study reaches primary completion

  1. giredestrantphase 3 · Jul 31 · NCT03332797
  2. trontinemabphase 3 · Jul 31 · NCT04639050

Hoffmann-La Roche, Aug ’27: 2 programs whose next study reaches primary completion

  1. RO7837195phase 2 · Aug 25 · NCT06979336
  2. bizrolertinibphase 3 · Aug 31 · NCT05593094

Hoffmann-La Roche, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zemocimigphase 3 · Sep 23 · NCT07416526

Hoffmann-La Roche, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. mosunetuzumabphase 3 · Oct 1 · NCT05207670
  2. emicizumabapproved, new study · Oct 6 · NCT06998524
Johnson & Johnson25 readouts · 8 phase 3·

Johnson & Johnson, Dec ’26: 9 programs whose next study reaches primary completion, 4 in phase 3

  1. anvatabart opadotinphase 2 · Dec 0 · NCT04829604
  2. milvexianphase 3 · Dec 8 · NCT05757869
  3. JNJ-89862175phase 1 · Dec 15 · NCT07223125
  4. nipocalimabphase 3 · Dec 15 · NCT05327114
  5. JNJ-64042056phase 2 · Dec 22 · NCT06544616

and 4 more — sign in to see them all

Johnson & Johnson, Jan ’27: 1 program whose next study reaches primary completion

  1. JNJ-86974680phase 1 · Jan 7 · NCT07319871

Johnson & Johnson, Feb ’27: 4 programs whose next study reaches primary completion, 3 in phase 3

  1. guselkumabapproved, new study · Feb 10 · NCT06260163
  2. icotrokinraphase 3 · Feb 10 · NCT06807424
  3. lazertinibphase 3 · Feb 12 · NCT04077463
  4. teclistamabapproved, new study · Feb 12 · NCT07030517

Johnson & Johnson, Mar ’27: 3 programs whose next study reaches primary completion

  1. Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387phase 1 · Mar 16 · NCT06178614
  2. deulumateperonephase 3 · Mar 16 · NCT06480383
  3. pasritamigphase 3 · Mar 31 · NCT04898634

Johnson & Johnson, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. lumateperonephase 3 · Apr 5 · NCT05850689
  2. ramantamigphase 3 · Apr 19 · NCT05652335
·

Johnson & Johnson, Jun ’27: 4 programs whose next study reaches primary completion

  1. Anti-CALRmut/Anti-CD3 Bispecific Antibody JNJ-88549968phase 1 · Jun 14 · NCT06150157
  2. Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401phase 3 · Jun 21 · NCT06095089
  3. Aticaprantphase 3 · Jun 21 · NCT07615426
  4. JNJ-88545223phase 2 · Jun 28 · NCT07321873
·

Johnson & Johnson, Aug ’27: 1 program whose next study reaches primary completion

  1. JNJ-90189892phase 1 · Aug 5 · NCT06651229
·

Johnson & Johnson, Oct ’27: 1 program whose next study reaches primary completion

  1. JNJ-88998377phase 1 · Oct 29 · NCT06470438
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Hoffmann-La Roche

New programs 4

  • RO7836748phase 1 · first study · Oct 23
  • RO7821657phase 1 · first study · Oct 14
  • RO7965032phase 2 · first study · Sep 25 · Geographic Atrophy
  • RO7830698phase 2 · first study · Sep 11 · Pulmonary Disease, Chronic Obstructive

Reached a new phase 1

Study stopped 1

  • RO7763505phase 1 · terminated Nov 17 · none of its studies left running“The development of RO7763505 for coronary artery disease has been discontinued.” · NCT07495813

Primary completion later 11

Johnson & Johnson

New programs 1

Reached a new phase 2

Study stopped 0

None

Primary completion later 3

Where they overlap

Conditions where at least two of them have programs: 23 in all. A program counts in each condition its studies name most.

ConditionHoffmann-La RocheJohnson & Johnson
Lymphoma, Non-Hodgkinboth · compare here

Hoffmann-La Roche in Lymphoma, Non-Hodgkin: 2 programs

  1. glofitamabphase 3
  2. mosunetuzumabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma, Non-Hodgkin in search

Carcinoma, Non-Small-Cell Lungboth · compare here

Hoffmann-La Roche in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. divarasibphase 3
  2. tambotatug pelitecanphase 2
  3. AQUA07phase 1
  4. lorlatinibphase 1

Their studies: Hoffmann-La Roche’s studies of Carcinoma, Non-Small-Cell Lung in search

Johnson & Johnson in Carcinoma, Non-Small-Cell Lung: 6 programs

  1. amivantamabphase 3
  2. lazertinibphase 3
  3. hafnium oxidephase 3
  4. anvatabart opadotinphase 2
  5. olomorasibphase 2

and 1 more — sign in to see them all

Their studies: Johnson & Johnson’s studies of Carcinoma, Non-Small-Cell Lung in search

Multiple Myelomaboth · compare here

Hoffmann-La Roche in Multiple Myeloma: 4 programs

  1. cevostamabphase 3
  2. hyaluronidase (human recombinant)phase 2
  3. RO7851624phase 1
  4. RO7875913phase 1

Their studies: Hoffmann-La Roche’s studies of Multiple Myeloma in search

Johnson & Johnson in Multiple Myeloma: 6 programs

  1. ramantamigphase 3
  2. fludarabinephase 2
  3. JNJ-102299639phase 1
  4. JNJ-87562761phase 1
  5. teclistamabapproved, new study

and 1 more — sign in to see them all

Their studies: Johnson & Johnson’s studies of Multiple Myeloma in search

Neoplasmsboth · compare here

Hoffmann-La Roche in Neoplasms: 4 programs

  1. inavolisibphase 3
  2. lorlatinibphase 1
  3. Pan-RAS Inhibitor RG6505phase 1
  4. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Neoplasms in search

Prostatic Neoplasmsboth · compare here

Hoffmann-La Roche in Prostatic Neoplasms: 3 programs

  1. inavolisibphase 3
  2. GDC-1261phase 2
  3. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Prostatic Neoplasms in search

Alzheimer Diseaseboth · compare here

Hoffmann-La Roche in Alzheimer Disease: 5 programs

  1. trontinemabphase 3
  2. RO7568282phase 2
  3. nivegacetorphase 2
  4. RO7812653phase 1
  5. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Alzheimer Disease in search

Johnson & Johnson in Alzheimer Disease: 3 programs

  1. lumateperonephase 3
  2. seltorexantphase 3
  3. JNJ-64042056phase 2

Their studies: Johnson & Johnson’s studies of Alzheimer Disease in search

Breast Neoplasmsboth · compare here

Hoffmann-La Roche in Breast Neoplasms: 6 programs

  1. inavolisibphase 3
  2. giredestrantphase 3
  3. bizrolertinibphase 3
  4. vustanaciclibphase 2
  5. GDC-0587phase 1

and 1 more — sign in to see them all

Their studies: Hoffmann-La Roche’s studies of Breast Neoplasms in search

Colorectal Neoplasmsboth · compare here

Hoffmann-La Roche in Colorectal Neoplasms: 5 programs

  1. inavolisibphase 3
  2. divarasibphase 3
  3. autogene cevumeranphase 2
  4. Lead Pb 203-DOTAMphase 1
  5. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Colorectal Neoplasms in search

Johnson & Johnson in Colorectal Neoplasms: 3 programs

  1. amivantamabphase 3
  2. olomorasibphase 2
  3. JNJ-89402638phase 1

Their studies: Johnson & Johnson’s studies of Colorectal Neoplasms in search

Colitis, Ulcerativeboth · compare here

Hoffmann-La Roche in Colitis, Ulcerative: 2 programs

  1. afimkibartphase 3
  2. RO7837195phase 2

Their studies: Hoffmann-La Roche’s studies of Colitis, Ulcerative in search

Johnson & Johnson in Colitis, Ulcerative: 4 programs

  1. icotrokinraphase 3
  2. JNJ-78934804phase 3
  3. risankizumabphase 3
  4. guselkumabapproved, new study

Their studies: Johnson & Johnson’s studies of Colitis, Ulcerative in search

Crohn Diseaseboth · compare here

Hoffmann-La Roche in Crohn Disease: 1 program

  1. afimkibartphase 3

Their studies: Hoffmann-La Roche’s studies of Crohn Disease in search

Johnson & Johnson in Crohn Disease: 4 programs

  1. icotrokinraphase 3
  2. JNJ-78934804phase 3
  3. risankizumabphase 3
  4. guselkumabapproved, new study

Their studies: Johnson & Johnson’s studies of Crohn Disease in search

Dermatitis, Atopicboth · compare here

Hoffmann-La Roche in Dermatitis, Atopic: 3 programs

  1. afimkibartphase 3
  2. astegolimabphase 3
  3. Cyclosporineapproved, new study

Their studies: Hoffmann-La Roche’s studies of Dermatitis, Atopic in search

Johnson & Johnson in Dermatitis, Atopic: 2 programs

  1. JNJ-95597528phase 2
  2. JNJ-95475939phase 2

Their studies: Johnson & Johnson’s studies of Dermatitis, Atopic in search

Leukemia, Lymphocytic, Chronic, B-Cellboth · compare here

Hoffmann-La Roche in Leukemia, Lymphocytic, Chronic, B-Cell: 2 programs

  1. mosunetuzumabphase 3
  2. bexobrutidegno phase

Their studies: Hoffmann-La Roche’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Johnson & Johnson in Leukemia, Lymphocytic, Chronic, B-Cell: 3 programs

  1. fludarabinephase 2
  2. safimaltibphase 1
  3. ibrutinibapproved, new study

Their studies: Johnson & Johnson’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Renal Insufficiencyboth · compare here

Hoffmann-La Roche in Renal Insufficiency: 3 programs

  1. petrelintidephase 3
  2. tifeglipronphase 2
  3. lorlatinibphase 1

Their studies: Hoffmann-La Roche’s studies of Renal Insufficiency in search

Johnson & Johnson in Renal Insufficiency: 2 programs

  1. seltorexantphase 3
  2. olomorasibphase 2

Their studies: Johnson & Johnson’s studies of Renal Insufficiency in search

Arthritis, Rheumatoidboth · compare here

Hoffmann-La Roche in Arthritis, Rheumatoid: 3 programs

  1. afimkibartphase 3
  2. fenebrutinibphase 3
  3. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Arthritis, Rheumatoid in search

Johnson & Johnson in Arthritis, Rheumatoid: 1 program

  1. nipocalimabphase 3

Their studies: Johnson & Johnson’s studies of Arthritis, Rheumatoid in search

Lupus Erythematosus, Systemicboth · compare here

Hoffmann-La Roche in Lupus Erythematosus, Systemic: 3 programs

  1. cevostamabphase 3
  2. fenebrutinibphase 3
  3. P-CD19CD20-ALLO1 Cellsphase 1

Their studies: Hoffmann-La Roche’s studies of Lupus Erythematosus, Systemic in search

Johnson & Johnson in Lupus Erythematosus, Systemic: 1 program

  1. nipocalimabphase 3

Their studies: Johnson & Johnson’s studies of Lupus Erythematosus, Systemic in search

Schizophreniaboth · compare here

Hoffmann-La Roche in Schizophrenia: 1 program

  1. ralmitarontphase 2

Their studies: Hoffmann-La Roche’s studies of Schizophrenia in search

Johnson & Johnson in Schizophrenia: 2 programs

  1. lumateperonephase 3
  2. Aticaprantphase 3

Their studies: Johnson & Johnson’s studies of Schizophrenia in search

Asthmaboth · compare here

Hoffmann-La Roche in Asthma: 1 program

  1. astegolimabphase 3

Their studies: Hoffmann-La Roche’s studies of Asthma in search

Johnson & Johnson in Asthma: 1 program

  1. JNJ-95597528phase 2

Their studies: Johnson & Johnson’s studies of Asthma in search

Carcinoma, Hepatocellularboth · compare here

Hoffmann-La Roche in Carcinoma, Hepatocellular: 1 program

  1. codrituzumabphase 2

Their studies: Hoffmann-La Roche’s studies of Carcinoma, Hepatocellular in search

Johnson & Johnson in Carcinoma, Hepatocellular: 1 program

  1. amivantamabphase 3

Their studies: Johnson & Johnson’s studies of Carcinoma, Hepatocellular in search

Lymphomaboth · compare here

Hoffmann-La Roche in Lymphoma: 1 program

  1. glofitamabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma in search

Johnson & Johnson in Lymphoma: 1 program

  1. fludarabinephase 2

Their studies: Johnson & Johnson’s studies of Lymphoma in search

Lymphoma, Large B-Cell, Diffuseboth · compare here

Hoffmann-La Roche in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. glofitamabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma, Large B-Cell, Diffuse in search

Johnson & Johnson in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. ibrutinibapproved, new study

Their studies: Johnson & Johnson’s studies of Lymphoma, Large B-Cell, Diffuse in search

Myasthenia Gravisboth · compare here

Hoffmann-La Roche in Myasthenia Gravis: 1 program

  1. hyaluronidase (human recombinant)phase 2

Their studies: Hoffmann-La Roche’s studies of Myasthenia Gravis in search

Johnson & Johnson in Myasthenia Gravis: 1 program

  1. nipocalimabphase 3

Their studies: Johnson & Johnson’s studies of Myasthenia Gravis in search

Non-Muscle Invasive Bladder Neoplasmsboth · compare here

Hoffmann-La Roche in Non-Muscle Invasive Bladder Neoplasms: 1 program

  1. eciskafusp alfaphase 1

Their studies: Hoffmann-La Roche’s studies of Non-Muscle Invasive Bladder Neoplasms in search

Johnson & Johnson in Non-Muscle Invasive Bladder Neoplasms: 1 program

  1. Erdafitinib-releasing Intravesical System TAR-210phase 3

Their studies: Johnson & Johnson’s studies of Non-Muscle Invasive Bladder Neoplasms in search

Stomach Neoplasmsboth · compare here

Hoffmann-La Roche in Stomach Neoplasms: 1 program

  1. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Stomach Neoplasms in search

Johnson & Johnson in Stomach Neoplasms: 1 program

  1. amivantamabphase 3

Their studies: Johnson & Johnson’s studies of Stomach Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Hoffmann-La Roche 39 of 80 · Johnson & Johnson 33 of 56 programs (37 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Hoffmann-La Roche: 25, Johnson & Johnson: 4).